Latest News From Lumira Ventures

Aurinia Demonstrates Voclosporin’s Superiority over Standard-of-Care in Lupus Nephritis

Jennifer Schram Aurinia Pharmaceuticals, Main Page, Portfolio News, Press Release

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions, today announced positive efficacy and safety results from its pivotal …

Notch Therapeutics Announces R&D Collaboration with Allogene worth up to $283M per Target

Jennifer Schram Main Page, Notch Therapeutics, Portfolio News, Press Release

SOUTH SAN FRANCISCO, Calif. and TORONTO — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Notch Therapeutics Inc., an immune cell therapy company creating universally compatible, …

Satsuma Pharmaceuticals Completes $90.8M Initial Public Offering

Jennifer Schram Main Page, Portfolio News, Press Release, Satsuma Pharmaceuticals

SOUTH SAN FRANCISCO, Calif. — Satsuma Pharmaceuticals, Inc. (“Satsuma” or the “Company”) (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced the closing of the Company’s previously announced initial public offering …